Kenvue (KVUE) Analyst Targets and Outlook: 2026 Investment Review

Kenvue Inc. (KVUE) shares have posted a 14.5% year‑to‑date gain while still down 11.7% over the past 52 weeks; analyst price targets and sentiment now hinge on the company’s turnaround initiatives.

Kenvue’s Turbulent 2026 Market Journey

■14.5% YTD rise, lagging the S&P 500 (16.3%)

■52‑week decline of 11.7%

■Market cap sits at $37.4 billion

■Underperformed the Consumer Staples SPDR (XLP) 7.9% over 52 weeks, yet outpaced its 12.1% YTD gain

Analyst Target Revisions and Sentiment Pulse

■Barclays lifted its price objective to $19 from $18

■Consensus target hovers around $18.5

■Coverage: 1 Strong Buy, 12 Hold recommendations

■Consensus rating: Hold

earnings Outlook: EPS and Margin Trajectory

■FY‑2026 EPS forecast $1.16, a 7.4% YoY increase

■Company has beat consensus estimates for four consecutive quarters

■Cost‑cutting and brand‑refresh programs aimed at margin expansion

Investor Mood and Sector Context

■Sluggish growth in the Skin Health & Beauty segment, with Neutrogena and Aveeno facing weak demand

■Retail inventory reductions and softer discretionary spending pressures

■Ongoing talc litigation inherited from Johnson & Johnson remains a legal cloud

■Investors are gravitating toward defensive consumer‑health stocks, prompting a re‑rating of KVUE

Markets are watching Kenvue’s operational efficiencies and brand revitalization closely. Cost discipline and upcoming product launches will be decisive for the stock’s long‑term trajectory, but lingering legal exposure and consumer demand volatility will keep the upside capped and the downside risk palpable.